☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
multiple cancer indications
Shreis Scalene's Cytotron Receives the US FDA's Breakthrough Device Designation for the Treatment of Multiple Cancer Indications
October 31, 2019
MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications
September 24, 2019
Teva Canada's Herzuma (biosimilar- trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications
September 12, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.